Sequence data for the *S*. *aureus fnbA* and *fnbB* genes are available from Genbank with the following accession numbers: KU057973-KU058113 and KU145155-KU145264.

Introduction {#sec005}
============

*Staphylococcus aureus* is a leading cause of prosthetic joint infection (PJI) \[[@pone.0141436.ref001],[@pone.0141436.ref002]\]. A hallmark of *S*. *aureus* PJI is the biofilm, a sessile community of bacteria fixed in an extracellular matrix of DNA, proteins and polysaccharides. Biofilms promote device-associated infection and are highly resistant to host defenses and antimicrobials \[[@pone.0141436.ref003]\]. Integral to the initiation of *S*. *aureus* biofilm formation are fibronectin binding protein A and B (FnBPA, FnBPB), members of the family of Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMMs) \[[@pone.0141436.ref004]--[@pone.0141436.ref007]\].

Our lab previously demonstrated that specific, non-synonymous single nucleotide polymorphisms (SNPs) in *fnbA* are associated with cardiac device infection (CDI) and stronger binding to fibronectin as determined by atomic force microscopy *in vitro* \[[@pone.0141436.ref008],[@pone.0141436.ref009]\]. This association between *fnbA* SNPs and CDI was recently validated \[[@pone.0141436.ref010]\]. However, it is unknown whether this association extends to *S*. *aureus* infections of other prosthetic devices, such as arthroplasties. The current study investigates potential associations between variation in *fnbA* and *fnbB* and the likelihood of arthroplasty infection in a patient with *S*. *aureus* bacteremia (SAB).

Materials and Methods {#sec006}
=====================

Source of *S*. *aureus* Isolates {#sec007}
--------------------------------

This study involved human participants and was approved by the IRB Committees at Duke University Medical Center, University of Cologne, and University Medical Center at Freiburg. Written consent to participate in the study was received from all participants. Adult patients with SAB were eligible for inclusion in the current analysis if they had a hip or knee arthroplasty present at time that *S*. *aureus* was isolated from ≥1 blood culture. Patients with polymicrobial infections were excluded (n = 1). Isolates from eligible patients were divided into two groups: a *derivation cohort* and a *validation cohort*.

*Derivation cohort*: Derivation cohort isolates were obtained from the *S*. *aureus* Bacteremia Group (SABG). SABG is an ongoing prospective cohort study at Duke University Medical Center (Durham, NC). The SABG database consists of prospectively ascertained clinical data, patient DNA, and bloodstream bacterial isolates from more than 2,000 consecutive consenting patients with SAB since 1994. SABG patients are evaluated prospectively during their hospital stays for source of infection, presence of prosthetic devices, hemodialysis dependency, clinical signs of *S*. *aureus* infection, length of stay, discharge status, and clinical outcome \[[@pone.0141436.ref011]\].

*Validation Cohort*: The validation cohort was derived from the INSTINCT (Invasive *S*. *aureus* Infection Cohort) study \[[@pone.0141436.ref012]\]. INSTINCT is conducted at two German centers: University of Cologne and University Medical Center Freiburg. INSTINCT has collected clinical data and bacterial isolates from more than 1,000 consecutive patients since 2006.

Clinical Definitions {#sec008}
--------------------

Two clinical categories were identified: prosthetic joint infected (PJI) and prosthetic joint uninfected (PJU). PJI was defined as isolation of *S*. *aureus* from the arthroplasty site during the initial episode of SAB. PJU was defined as no evidence of device infection at the time of the initial episode of SAB, retention of the arthroplasty, and no evidence of infected arthroplasty or recurrent infection 12 weeks after the initial onset of SAB. Bacterial isolates were obtained from the initial blood culture specimens to allow for better comparison of PJI and PJU (e.g., there were no isolates from uninfected joints by definition). Early infection was defined as SAB occurring \<1 year after prostheses implantation or manipulation. Late infection was defined as SAB occurring \>1 year after placement or manipulation of prostheses.

Amino Acid Polymorphisms in FnBPA and FnBPB {#sec009}
-------------------------------------------

Each *S*. *aureus* isolate underwent genomic DNA extraction using an Ultraclean Microbial DNA Isolation kit (MO BIO). The DNA then underwent high-fidelity PCR amplification of *fnbA* and *fnbB*. The resulting fragments were sequenced in the forward and reverse directions to obtain the full sequence length of the *fnbA* and *fnbB* binding regions \[[@pone.0141436.ref009]\]. Their nucleotide and predicted amino acid sequences (FnBPA and FnBPB, respectively) were compared with the respective reference sequences obtained from *S*. *aureus* NCTC 8325--4 by the ClustalW method using DNASTAR and Vector NTI \[[@pone.0141436.ref009]\]. These experiments were repeated for the isolates from the external validation cohort \[[@pone.0141436.ref010]\] by investigators (EME, BSK, THR) who were blinded to the clinical designation (i.e., PJI vs. PJU) of the isolates.

Genotyping of Bacterial Isolates by *spa* Typing {#sec010}
------------------------------------------------

Genomic DNA was prepared as described above. Each DNA isolate underwent high-fidelity PCR with specifically designed forward and reverse primers to amplify the *spa* region \[[@pone.0141436.ref013]\]. The resulting PCR fragment underwent DNA purification and sequencing at the Duke University sequencing laboratory. The Ridom SpaServer ([www.spaserver.ridom.de](http://www.spaserver.ridom.de)) was used to map the resulting sequences to the corresponding *spa* type and clonal complex.

Fibronectin Binding Assay {#sec011}
-------------------------

An assay with slight modification from that of Peacock *et al*. \[[@pone.0141436.ref014]\] was used to determine *S*. *aureus* binding to fibronectin *in vitro*. Briefly, 96-well BD Falcon plates were coated with 100 μL human fibronectin (10 μg/mL, Sigma) overnight at 4°C. The plates were washed with phosphate-buffered saline (PBS) and then blocked with 100 μL of 2% bovine serum albumin solution for 1 hour at 37°C. Wells were washed and 100 μL bacteria collected from overnight TSB cultures and adjusted in PBS to optical density 1.0 at 600 nm (corresponding to 10^7^ cells/mL) were added in quadruplicate and incubated for 2 hours at 37°C. The wells were washed again with 100 μL PBS. Bacteria were fixed with 100 μL of 25% formaldehyde solution for 10 minutes. Then 100 μL of a 0.5% crystal violet (Sigma) solution was added to each well for 1 minute. Finally, 100 μL dimethyl sulfoxide was added to each well before absorbance was read at 620 nm using a Multiskan Ascent 354 Plate Reader (Thermo Labsystems). Absorbance values were then expressed as percentage of the values obtained for *S*. *aureus* 8325--4 on the same plate. Each strain underwent a total of three fibronectin binding assays, the results of which were averaged.

Biofilm Assay {#sec012}
-------------

The biofilm assay was performed as described by Sharma-Kuinkel *et al*. \[[@pone.0141436.ref015]\] and Beenken *et al*. \[[@pone.0141436.ref016]\] with slight modifications. Briefly, 96-well BD Falcon plates were coated with 200 μL of 20% human plasma (Sigma) in carbonate buffer (pH 9.6, 0.05M) overnight at 4°C. The plasma was then discarded from each well. Next, 200 μL bacteria grown overnight in TSB-NaCl-glucose broth and then adjusted to optical density 0.05 at 600 nm was added in quadruplicate to the wells and incubated for 24 hours at 37°C. The cultures were discarded from the wells and the plate washed with 200 μL PBS. Biofilms were fixed using 200 μL of 100% ethanol for 2 minutes at room temperature. The wells were then stained with 100 μL of 0.41% crystal violet in 12% ethanol for 2 minutes at room temperature, then washed with 200 μL PBS. Biofilms were dried at room temperature overnight and then solubilized with 100 μL of 100% ethanol for 10 minutes at room temperature. Absorbance was read at 620 nm using a Multiskan Ascent 354 Plate Reader (Thermo Labsystems). Each plate included a positive control *S*. *aureus* strain known to form biofilm (UAMS-1), another *S*. *aureus* strain that weakly forms a biofilm (8325--4), and a negative control (medium only) \[[@pone.0141436.ref016],[@pone.0141436.ref017]\]. The capacity to form a biofilm was compared against these strains. Bacterial isolates were deemed to have a proteinaceous matrix when they satisfied two conditions: 1) no biofilm formed when grown in the presence of 2 μg/mL proteinase K \[[@pone.0141436.ref018]\], and 2) dissolution of biofilm when 2 μg/mL proteinase K was added to 36-hour biofilms and incubated for 24 hours. The biofilm matrix composition of one PJI isolate and one PJU isolate were tested.

Quantitative PCR {#sec013}
----------------

To evaluate the possibility that variable expression of *fnbA* could be associated with risk of PJI, a random sample of isolates (7 PJI, 7 PJU) from the derivation cohort underwent quantitative PCR to determine expression levels of *fnbA*. Isolates with multiple SNPs and isolates with few to no SNPs were equally represented within each group. The 18 isolates along with positive control (8325--4) were grown overnight in 10 mL liquid TSB media at 37°C. Bacteria collected from the overnight cultures and adjusted to an OD 0.1 at 600 nm were added to 10 mL fresh TSB liquid media and incubated at 37°C for 4 hours. RNA was then extracted from each isolate using the RNeasy Mini Kit (Qiagen). RNA concentrations were measured using a NanoDrop (Thermo Scientific) to measure the ratio of UV absorption at 260 nm and 280 nm. Next, cDNA was synthesized via RT-PCR from each RNA template using the BIO-RAD iScript cDNA Synthesis kit (170--8890). Then 2 μL cDNA was added to 96-well PCR plates in duplicate. Specially designed forward and reverse *fnbA* primers and the BIO-RAD SYBR Green Supermix (152--7560) were added to the cDNA as detailed by the BIO-RAD qPCR protocol. The plate was then placed in the BIO-RAD qPCR/Real Time PCR machine, and the fluorescence intensity was measured following each amplification cycle.

Western Ligand Affinity Blotting {#sec014}
--------------------------------

Western ligand affinity blotting was performed as previously described \[[@pone.0141436.ref004]\], with modifications. Briefly, overnight cultures were diluted 1:50 in TSB medium and grown at 37°C with shaking for 4 hours. Cells were washed and surface-associated protein extracts were prepared through resuspension in PBS media containing 20 μg/mL lysostaphin (Sigma), 20 μg/mL DNAse (New England Biolabs), 1 mM phenylmethanesulfonylfluoride (PMSF, Thermo Scientific), and 1:100 dilution of a protease inhibitor cocktail (Sigma, P2714). Cell extracts were incubated at 37°C for 30 minutes and spun at 12,000 x g for 1 minute at 4°C. The protein concentration in the supernatant was determined with a BCA Protein Assay Kit (Pierce), and 20 μg of each sample was separated via sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). FnBPs were detected by incubation for 1 hour with biotinylated human fibronectin (50 μg/mL) in PBS containing 0.1% Tween 20 (PBST). An EZ-Link sulfo-*N*-hydroxysuccinimide-LC biotinylation kit (Pierce) was used to biotinylate human fibronectin (Sigma). After washing with PBST, membranes were incubated for 1 hour with streptavidin-peroxidase conjugate (Roche; 1:3000 dilution). Finally, membranes were developed with the ECL Western blotting system (Pierce). A *S*. *aureus fnbA fnbB* double mutant \[[@pone.0141436.ref019]\] was used as a negative control.

Statistical Analysis {#sec015}
--------------------

Data were presented as frequency counts and corresponding percentages for categorical factors, and means for continuous variables \[[@pone.0141436.ref013]\]. Fisher's Exact Test and unpaired t-tests with an alpha = 0.05 were used to calculate significance using Microsoft Excel and JMP Pro 10.2. Given that multiple comparisons (i.e., multiple SNPS) were tested, a false discovery rate procedure was applied to the raw p-values to correct for false associations \[[@pone.0141436.ref020]\]. Raw p-values are displayed in Tables [1](#pone.0141436.t001){ref-type="table"}, [2](#pone.0141436.t002){ref-type="table"} and [3](#pone.0141436.t003){ref-type="table"}, with exception as noted in Tables [2](#pone.0141436.t002){ref-type="table"} and [3](#pone.0141436.t003){ref-type="table"}. A p-value \<0.05 was considered statistically significant \[[@pone.0141436.ref013]\].

10.1371/journal.pone.0141436.t001

###### Demographic and clinical characteristics of patients in the derivation cohort with *S*. *aureus* bacteremia and infected or uninfected prostheses.

![](pone.0141436.t001){#pone.0141436.t001g}

  CHARACTERISTICS                              PROSTHETIC JOINT INFECTION (n = 27)   PROSTHETIC JOINT UNINFECTED (n = 43)   P-value
  -------------------------------------------- ------------------------------------- -------------------------------------- ---------
  **SEX**                                                                                                                   
   Female                                      18 (67%)                              25 (58%)                               0.62
  **RACE**                                                                                                                  
   Black                                       5 (19%)                               13 (30%)                               0.40
   White                                       22 (81%)                              30 (70%)                               
  **COMORBIDITIES**                                                                                                         
   Diabetes mellitus                           6 (22%)                               19 (44%)                               0.08
   Hemodialysis                                1 (4%)                                6 (14%)                                0.24
   Cancer                                      4 (15%)                               5 (12%)                                0.73
  **TIMING OF INFECTION**                                                                                                   
   Early                                       10 (37%)                              3 (7%)                                 0.002
   Late[\*](#t001fn001){ref-type="table-fn"}   17 (63%)                              40 (93%)                               
  **METHICILLIN RESISTANCE**                                                                                                
                                               12 (44%)                              27 (69%)                               0.15
  **MEAN AGE**                                                                                                              
                                               61 (range 20--81)                     66 (range 33--88)                      0.15
  **DEVICE**                                                                                                                
   Hip                                         17 (52%)                              24 (56%)                               0.62
   Knee                                        10 (37%)                              18 (42%)                               0.80
   Both                                        0                                     1 (2%)                                 1.00

\*Late infection is defined as bloodstream infection occurring \>1 year after the prostheses was implanted or surgically manipulated.

10.1371/journal.pone.0141436.t002

###### Single Nucleotide Polymorphisms (SNPs) in fibronectin binding protein A (*fnbA)* in the derivation cohort, external validation cohort, and late *S*. *aureus* bacteremia (SAB) group.

In the derivation cohort, no SNPs occurred with greater frequency in the prosthetic joint infection group (PJI) relative to the uninfected prosthetic joint group (PJU). In the external validation cohort, one SNP (S839N) was significantly associated with the PJU group, though when the two cohorts were combined the S839N association did not reach statistical significance (p = 0.22). Late SAB was defined as bacteremia occurring \>1 year after placement or manipulation of prostheses, and here contains data from both the derivation and external validation cohorts. In the late SAB group, no SNPs occurred with greater frequency in PJI or PJU.

![](pone.0141436.t002){#pone.0141436.t002g}

  NONSYNONYMOUS SNP   DERIVATION COHORT   EXTERNAL VALIDATION COHORT   LATE *S*. *AUREUS* BACTEREMIA                                                                   
  ------------------- ------------------- ---------------------------- ------------------------------- ---- ---- ------------------------------------------- ---- ---- ------
  **REPEAT 1**                                                                                                                                                         
  T539K               1                   0                            0.39                            0    2    1.00                                        1    0    0.25
  **REPEAT 2**                                                                                                                                                         
  G563E               3                   6                            1.00                            1    11   0.68                                        4    17   0.58
  **REPEAT 5**                                                                                                                                                         
  E652D               2                   5                            0.70                            0    10   0.19                                        4    15   0.78
  V668I               2                   0                            0.15                            \-   \-                                               1    0    0.25
  **REPEAT 6**                                                                                                                                                         
  S678I               1                   0                            0.15                            0    2    1.00                                        0    0    1.00
  V698I               4                   8                            0.76                            0    14   0.11                                        4    20   0.42
  K703E               27                  40                           0.28                            2    24   0.19                                        16   47   1.00
  **REPEAT 7**                                                                                                                                                         
  D723G               4                   7                            1.00                            0    15   0.06                                        4    19   0.42
  **REPEAT 8**                                                                                                                                                         
  G741S               \-                  \-                           \-                              1    0    0.17                                        1    0    0.25
  N750D               1                   0                            0.39                            0    2    1.00                                        0    0    1.00
  **REPEAT 9**                                                                                                                                                         
  P779T               \-                  \-                           \-                              0    7    0.34                                        0    1    1.00
  H782Q               1                   0                            0.39                            0    2    1.00                                        0    2    1.00
  K786N               3                   6                            0.39                            0    13   0.11                                        1    13   0.11
  N788D               \-                  \-                           \-                              0    2    1.00                                        0    2    1.00
  K797E               \-                  \-                           \-                              0    3    1.00                                        0    2    1.00
  **REPEAT 10**                                                                                                                                                        
  H804Q               2                   2                            0.64                            0    2    1.00                                        1    2    1.00
  H818Q               1                   0                            0.39                            0    2    1.00                                        0    0    1.00
  T826N               2                   0                            0.15                            0    3    1.00                                        1    0    0.25
  **REPEAT 11**                                                                                                                                                        
  S839N               6                   10                           1.00                            0    20   0.01[\*](#t002fn001){ref-type="table-fn"}   5    25   0.23
  N846S               \-                  \-                           \-                              0    2    1.00                                        0    1    1.00
  S847I               \-                  \-                           \-                              0    1    1.00                                        0    1    1.00
  K857H/Q             0                   1                            1.00                            0    2    1.00                                        0    2    1.00
  Q861H               0                   1                            1.00                            0    2    1.00                                        0    2    1.00

\*When false discovery rate control is applied, this raw p-value no longer maintains statistical significance (p = 0.22).

10.1371/journal.pone.0141436.t003

###### Single Nucleotide Polymorphisms (SNPs) in fibronectin binding protein B (*fnbB)* in *fnbB-*containing isolates.

No SNP was associated with the prosthetic joint infected (PJI) or uninfected (PJU) isolates in the derivation cohort, external validation cohort, or late *S*. *aureus* bacteremia (SAB) group. Late SAB was defined as SAB occurring \>1 year after placement or manipulation of prostheses.

![](pone.0141436.t003){#pone.0141436.t003g}

  NONSYNONYMOUS SNP   DERIVATION COHORT   EXTERNAL VALIDATION COHORT   LATE *S*. *AUREUS* BACTEREMIA                             
  ------------------- ------------------- ---------------------------- ------------------------------- ---- ---- ------ --- ---- -------------------------------------------
  **REPEAT 1**                                                                                                                   
  E458D               3                   4                            1.00                            5    28   0.76   5   27   0.28
  E462D               0                   1                            1.00                            1    2    0.43   1   2    0.54
  H463K               3                   3                            0.66                            5    27   1.00   6   26   0.59
  T465E               3                   3                            0.66                            5    27   1.00   7   27   0.79
  E468D               1                   0                            0.38                            1    15   0.27   2   15   0.33
  E470D               3                   3                            0.66                            4    25   0.75   5   19   1.00
  F471I               3                   3                            0.66                            5    28   0.76   7   27   0.79
  P475Q               1                   2                            1.00                            0    5    0.58   1   3    1.00
  T483N               0                   1                            1.00                            1    1    0.32   1   2    0.54
  **REPEAT 2 or 3**                                                                                                              
  A506V               2                   3                            1.00                            1    8    1.00   3   11   1.00
  A510V               1                   1                            1.00                            \-   \-   \-     0   0    1.00
  T513I               5                   7                            1.00                            7    28   0.75   7   27   0.79
  I514V               3                   1                            0.15                            2    13   1.00   4   13   1.00
  **REPEAT 4**                                                                                                                   
  H530L               1                   0                            0.38                            0    2    1.00   1   0    0.23
  **REPEAT 5**                                                                                                                   
  T554I               1                   1                            1.00                            \-   \-   \-     0   1    1.00
  D565E               1                   3                            1.00                            4    24   0.75   5   25   0.41
  V570L               1                   1                            1.00                            \-   \-   \-     0   1    1.00
  I581V               5                   8                            1.00                            8    31   0.53   9   26   0.60
  **REPEAT 6**                                                                                                                   
  P601L               \-                  \-                           \-                              0    2    1.00   0   2    1.00
  E602K               \-                  \-                           \-                              2    10   1.00   2   9    1.00
  **REPEAT 7**                                                                                                                   
  N618Y               2                   4                            1.00                            4    19   1.00   5   16   1.00
  H619Q               2                   4                            1.00                            4    21   1.00   5   19   1.00
  G633S               1                   0                            0.38                            1    0    0.17   2   0    0.05[\*](#t003fn001){ref-type="table-fn"}
  S645T               \-                  \-                           \-                              1    0    0.17   1   0    0.23
  **REPEAT 9**                                                                                                                   
  H696Q               3                   5                            1.00                            0    10   0.19   2   14   0.34
  N700K               3                   4                            1.00                            0    5    0.58   2   9    1.00
  N702D               9                   19                           0.37                            5    32   0.53   9   40   0.27
  K711E               2                   4                            1.00                            1    7    1.00   3   9    1.00
  **REPEAT 10**                                                                                                                  
  Q718H               1                   2                            1.00                            0    5    0.58   0   0    1.00
  I723L               \-                  \-                           \-                              0    2    1.00   0   1    1.00
  H732Q               2                   2                            0.63                            2    9    1.00   3   11   1.00
  T740N               3                   2                            0.36                            8    27   0.34   8   26   1.00
  **REPEAT 11**                                                                                                                  
  N753S               1                   0                            0.38                            \-   \-   \-     0   0    1.00
  N760S               5                   8                            1.00                            1    7    1.00   4   8    0.45
  S761G               1                   0                            0.38                            \-   \-   \-     0   0    1.00
  V761I               1                   0                            0.38                            \-   \-   \-     0   0    1.00
  E765V               1                   0                            0.38                            \-   \-   \-     0   0    1.00
  Q771K               1                   1                            1.00                            3    9    0.42   3   7    0.69
  G774V               2                   0                            0.14                            0    2    1.00   2   1    0.13
  H775Q               1                   1                            1.00                            2    7    0.65   3   5    0.37
  S761I               \-                  \-                           \-                              0    2    1.00   0   2    1.00
  T781N               \-                  \-                           \-                              0    1    1.00   0   0    1.00

\*When false discovery rate control is applied, this raw p-value no longer maintains statistical significance (p = 1.00).

Results {#sec016}
=======

Clinical Characteristics of Derivation Cohort {#sec017}
---------------------------------------------

The derivation cohort contained *S*. *aureus* bloodstream isolates from 70 unique patients (27 PJI; 43 PJU). Patients in the two clinical groups were similar with respect to sex, race, age, medical comorbidities, infection with MRSA, and joint location ([Table 1](#pone.0141436.t001){ref-type="table"}). Significantly more patients in the PJI group had early infection (10/27 vs 3/43; p = 0.002), likely because of an increased risk of arthroplasty infection in the perioperative period.

*spa* Typing {#sec018}
------------

A total of 24 different *spa* types were identified in the derivation cohort. Of these, *spa* types 2 (24 isolates; 34.3%), 12 (8 isolates; 11.4%), and 18 (6 isolates; 8.6%) were most common. The *spa* types were mapped to the broader categories of clonal complexes (CC). The most prevalent CC in the derivation cohort was CC5 (24 isolates, 34.3%) followed by CC30 (14 isolates, 20.0%).

A total of 38 different *spa* types were identified in the validation cohort. Of these, *spa* type 2 (8 isolates; 11.4%), *spa* type 91 (7 isolates; 10%), and *spa* type 3 (5 isolates; 7.1%) were the most common. When these *spa* types were mapped to corresponding CC, CC5 (15 isolates, 21.4%), CC7 (7 isolates, 10%), CC15 (6 isolates, 8.6%), and CC45 (6 isolates, 8.6%) predominated.

CC30 was significantly more common in the derivation cohort as compared to the validation cohort (14/70 \[20%\] isolates vs. 4/70 \[5.7%\] isolates, p = 0.01). Conversely, CC7 and CC45 were significantly more common in the validation cohort (CC7: 7/70 \[10%\] isolates vs. 0 isolates, p = 0.01; CC45: 6/70 \[8.6%\] isolates vs 0 isolates, p = 0.03) ([Fig 1](#pone.0141436.g001){ref-type="fig"}). Overall, there was no significant association between any of the CC and clinical group (i.e., PJI or PJU).

![Distribution of clonal complexes amongst *S*. *aureus* bloodstream isolates in the derivation and external validation cohorts.\
Clonal Complex 30 (CC30) was significantly more common in the derivation cohort (p = 0.01), while CC7 and CC45 were significantly more common in the external validation cohort (p = 0.01 and p = 0.03, respectively).](pone.0141436.g001){#pone.0141436.g001}

Sequencing of *fnbA* {#sec019}
--------------------

All 70 isolates in the derivation cohort contained the *fnbA* gene, as determined by PCR. A total 17 different non-synonymous SNPs were found in the fibronectin binding regions of *fnbA*. Fifteen of the 17 SNPs were found in the PJI isolates and 10/17 SNPs were found in the PJU isolates (88.2% vs 58.8%; p = 0.11) ([Fig 2A](#pone.0141436.g002){ref-type="fig"}). In the derivation cohort, no SNP was significantly more common in either of the clinical groups ([Table 2](#pone.0141436.t002){ref-type="table"}). This includes the three SNPs that were previously associated with cardiac device infection \[[@pone.0141436.ref009],[@pone.0141436.ref010]\]--E652D (p = 0.70), H782Q (p = 0.39), and K786N (p = 0.39). The lack of association between SNP frequency and clinical group remained when bacteria were analyzed within their individual clonal complexes (data not shown).

![Single Nucleotide Polymorphisms (SNPs) in the binding regions (Repeats 1--11) of fibronectin binding protein A (FnBPA) in the derivation cohort (A) and external validation cohort (B).\
Red boxes indicate SNPs that were only present in isolates from the prosthetic joint infection group (PJI), blue boxes indicate SNPs that were only present in the uninfected (PJU) group, and purple boxes indicate SNPs that were present in both PJI and PJU isolates.](pone.0141436.g002){#pone.0141436.g002}

Sequencing of *fnbB* {#sec020}
--------------------

A total 18 (66.7%) PJI isolates and 29 (67.4%) PJU isolates in the derivation cohort possessed *fnbB* (p = 1.00), as determined by PCR. Overall, 36 different non-synonymous SNPs were found in the binding regions of the 47 isolates containing this gene ([Fig 3A](#pone.0141436.g003){ref-type="fig"}). Thirty-four of these 36 SNPs (94.4%) were found in the PJI group, and 28/36 SNPs (60.0%) were found in the PJU group (p = 0.08). None of the individual SNPs were significantly more common in either of the clinical groups ([Table 3](#pone.0141436.t003){ref-type="table"}). This lack of association between SNP frequency and clinical group remained when bacteria were analyzed within their individual clonal complexes (data not shown).

![Single Nucleotide Polymorphisms (SNPs) in the binding regions (Repeats 1--11) of fibronectin binding protein B (FnBPB) in the derivation cohort (A) and the external validation cohort (B).\
Red boxes indicate SNPs that were only present in isolates from the prosthetic joint infection group (PJI), blue boxes indicate SNPs that were only present in the uninfected (PJU) group, and purple boxes indicate SNPs that were present in both PJI and PJU isolates.](pone.0141436.g003){#pone.0141436.g003}

Fibronectin Binding and Biofilm Formation {#sec021}
-----------------------------------------

Bacterial isolates within the two clinical groups of the derivation cohort exhibited a similar capacity for fibronectin binding (mean fibronectin binding: PJI 87.1% vs PJU 87.3%; p = 0.97) ([Fig 4](#pone.0141436.g004){ref-type="fig"}) and ability to form biofilm (mean biofilm formation: PJI 90.0% vs PJU 104.7%; p = 0.23) ([Fig 5](#pone.0141436.g005){ref-type="fig"}). Representative PJI and PJU isolates were tested and found to have proteinaceous biofilm matrices. Neither clinical grouping, particular *fnbA* SNPs, nor particular *fnbB* SNPs were significantly associated with reduced fibronectin binding or capacity to form biofilm. In addition, increased fibronectin binding was not significantly correlated with degree of biofilm formation (Pearson correlation coefficient r = 0.06; [S1 Fig](#pone.0141436.s001){ref-type="supplementary-material"}).

![Comparison of the fibronectin binding capacity of *S*. *aureus* isolates from prosthetic joint infection (PJI) and uninfected prosthetic joint (PJU) groups.\
Values were calculated as percentage capacity to bind fibronectin relative to *S*. *aureus* control strain 8325--4. Box ends represent the 25^th^ and 75^th^ percentiles, and whisker ends represent the minimum and maximum. There was no difference in fibronectin binding capacity between isolates in the PJI and PJU groups.](pone.0141436.g004){#pone.0141436.g004}

![Comparison of the biofilm-forming capacity of *S*. *aureus* isolates from prosthetic joint infection (PJI) and uninfected prosthetic joint (PJU) groups.\
Values were calculated as percentage capacity to form biofilms relative to *S*. *aureus* control strain UAMS-1. Box ends represent the 25^th^ and 75^th^ percentiles, and whisker ends represent the minimum and maximum. There was no difference in biofilm-forming capacity between isolates in the PJI and PJU groups.](pone.0141436.g005){#pone.0141436.g005}

*fnbA*/FnBPA Expression {#sec022}
-----------------------

Twenty percent (14 isolates) of the derivation cohort was randomly selected to assess level of *fnbA* RNA expression. The absorbance reading values obtained through RT-PCR were reported as fold-change in RNA expression relative to control 8325--4. The level of *fnbA* expression was not significantly different between the PJI and PJU isolates (p = 0.56) ([Fig 6A](#pone.0141436.g006){ref-type="fig"}). In addition, a Western ligand affinity blot using biotinylated human fibronectin was used to assess the expression of *S*. *aureus* fibronectin-binding proteins in a subset of isolates (5 PJI, 5 PJU). The bacterial isolates were chosen at random, and the PJI and PJU isolates were similar with respect to antibiotic susceptibility (i.e., MSSA vs. MRSA), timing of bacteremia (i.e., early vs. late) and site of prostheses. Though there was variation in fibronectin-binding protein expression, no clear difference between the PJI and PJU isolates was observed ([Fig 6B](#pone.0141436.g006){ref-type="fig"}). This assay measures all fibronectin-binding proteins and is not specific to FnBPA and FnBPB.

![Fibronectin binding protein A (*fnbA)* RNA expression (A) and fibronectin binding proteins (FnBPs) expression (B) in randomly selected *S*. *aureus* bloodstream isolates from patients with infected (PJI) and uninfected (PJU) prosthetic hip or knee joints.\
(A) RNA expression is represented as percent *fnbA* expression relative *to S*. *aureus* control 8325--4. Box ends represent the 25^th^ and 75^th^ percentiles, and whisker ends represent the minimum and maximum. There is no significant difference in *fnbA* expression between the two groups. (B) Fibronectin-binding protein expression was determined with Western ligand affinity blotting. There is no major difference in expression between the two clinical groups. Protein size (kilodaltons) is displayed and the double mutant *fnbAB* is included as a control.](pone.0141436.g006){#pone.0141436.g006}

Validation Cohort {#sec023}
-----------------

The validation cohort contained 70 patients: 12 PJI (17.1%), and 58 PJU (82.9%). Twenty-two distinct SNPs in *fnbA* identified in the validation cohort isolates were present in at least one of the PJU isolates, while only 3 were present in PJI isolates (22/22 \[100%\] in PJU vs 3/22 \[13.6%\] in PJI; p = 0.001) ([Fig 2B](#pone.0141436.g002){ref-type="fig"}). Of the 22 SNPs identified, one SNP (S839N) was more common in the PJU group as compared to the PJI group (p = 0.01) ([Table 2](#pone.0141436.t002){ref-type="table"}). After adjustment for multiple comparisons, however, the statistical significance of this finding was lost (p = 0.22). When the derivation and external validation cohorts were combined, the S839N SNP was not associated with the PJU group (p = 0.09).

Of the 70 validation cohort isolates, 66 contained *fnbB* (94.3%). The presence of *fnbB* was not associated with orthopedic device infection (66.7% PJI vs 67.4% PJU, p = 1.00). Among isolates with *fnbB* in the validation cohort, 35 distinct SNPs were found in the fibronectin-binding region of *fnbB*. Twenty-five SNPs (71.4%) were found in the PJI group and 33 (9.3%) in the PJU group (p = 0.02) ([Fig 3B](#pone.0141436.g003){ref-type="fig"}). There were no *fnbB* SNPs that occurred with greater frequency in the PJI group versus the PJU group ([Table 3](#pone.0141436.t003){ref-type="table"}). When the derivation and external validation cohorts were combined, there were similarly no *fnbB* SNPs associated with PJI or PJU.

Early Versus Late PJI {#sec024}
---------------------

Given that early PJI and late PJI are likely to involve different mechanisms of pathogenesis (e.g., early PJI from a primary surgical site infection; late PJI from hematogenous seeding), we evaluated *fnbA* and *fnbB* SNPs within these two clinical groups separately. Interestingly, an *fnbB* SNP (G633S) was associated with PJI in the late SAB group when the derivation and validation cohorts were combined (PJI: 2/18 \[11%\]; PJU: 0/61 \[0%\]; p = 0.05). However, the statistical significance of this relationship was not maintained after adjustment for multiple comparisons (p = 1.00) ([Table 3](#pone.0141436.t003){ref-type="table"}). There were no other significant associations between *fnbB* SNPs and PJI or PJU in the early or late SAB groups. No *fnbA* SNPs were associated with either PJI or PJU in either the early or late SAB groups ([Table 2](#pone.0141436.t002){ref-type="table"}).

Discussion {#sec025}
==========

The biological basis of *S*. *aureus* prosthetic device infections is incompletely understood. The current investigation evaluates whether the association that exists between *fnbA* SNPs and cardiac device infection extends to arthroplasties. Our study demonstrates that, unlike cardiac devices, *S*. *aureus* infection of arthroplasties is not associated with polymorphisms in the fibronectin binding protein genes, increased fibronectin binding, or biofilm formation capacity. This finding has several important implications.

In contrast to what our lab \[[@pone.0141436.ref009]\] and others \[[@pone.0141436.ref010]\] reported in *S*. *aureus* cardiac device infections, no SNPs in *S*. *aureus fnbA* were associated with infections of arthroplasties. Of the 17 distinct SNPs found in the *fnbA* binding region of the derivation cohort, no single mutation occurred with greater frequency in the PJI group versus the PJU group. In particular, the three SNPs that were previously shown to be associated with cardiac device infections---E652D, H782Q, and K786N --were all present in both the derivation and validation cohorts though not statistically associated with PJI. There are a few possible explanations for this intriguing difference between *S*. *aureus* PJI and cardiac device infection. First, cardiac devices such as pacemakers and cardioverter defibrillators are endovascular. Thus, they are subject to high levels of blood flow, exposure to various blood components and host proteins, and hemodynamic shear stress. In contrast, arthroplasties are extravascular, exist within a "sanctuary space", and are exposed to a different array of proteins and flow stress dynamics.

Second, cardiac devices are coated shortly after implantation with a proteinaceous fibrin sheath composed of host proteins including fibronectin and fibrinogen \[[@pone.0141436.ref003],[@pone.0141436.ref021]--[@pone.0141436.ref024]\]. The deposition of these host proteins on the endovascular components of cardiac devices significantly enhances adherence of *S*. *aureus* to the device \[[@pone.0141436.ref021]\]. By contrast, arthroplasties do not develop a fibrin sheath \[[@pone.0141436.ref025]\]. They are instead coated with osteopontin, bone sialoprotein and α~2~ HS-glycoprotein \[[@pone.0141436.ref025]\]. It is believed that these proteins accumulate because they contain polyacidic sequences (Asp-Gly-Asp) that promote cell adhesion \[[@pone.0141436.ref025]\]. Recent studies characterizing bone sialoprotein binding protein (*bbp*) of *S*. *aureus* have speculated that this MSCRAMM may be an important molecular player in the pathogenesis *S*. *aureus* osteomyelitis and PJI \[[@pone.0141436.ref026],[@pone.0141436.ref027]\]. Through riboprinting, Campoccia et al. found that *bbp*, the gene encoding for bone sialoprotein binding protein in *S*. *aureus*, was highly prevalent (94%) in *S*. *aureus* isolates causing orthopedic device infections. Additionally, studies in rabbit models have suggested that *bbp* is generally only harbored by virulent *S*. *aureus* strains \[[@pone.0141436.ref028]\].

Third, cardioverter defibrillators, pacemakers, and their leads contain different materials than those in arthroplasties. The pacemaker generator and lithium battery are encased in a metal, typically titanium, while the leads are coated with polyurethane or silicone rubber \[[@pone.0141436.ref029],[@pone.0141436.ref030]\]. By contrast, the femoral component of hip arthroplasties usually contains steel, cobalt-chromium alloys, or titanium alloys, while the cup component may contain ceramic, cobalt-chromium or polytetrafluoroethylene (PTFE, Teflon) \[[@pone.0141436.ref031]\].

Given the distinct properties of cardiac devices and arthroplasties, we speculate that the association between cardiac device infections and the presence of *fnbA* SNPs may be due at least in part to the unique conditions associated with such endovascular infections that are absent in orthopedic implants. Additionally, we propose that there may be other bacterial and/or host factors that predispose certain patients to PJI. Further research is underway to elucidate which factors those may be.

The current study also considered the potential role of *fnbB* in prosthetic device infection. Previous work demonstrated that *S*. *aureus* strains isolated from invasive disease often possess both *fnbA* and *fnbB* \[[@pone.0141436.ref014]\]. We show here that the absence of *fnbB* does not prevent *S*. *aureus* from causing PJI, as 20% of the 27 isolates associated with PJI lacked *fnbB* by PCR. Similarly, the presence of *fnbB* was not associated with orthopedic device infection. This result is consistent with a past study that similarly found no association between the presence of *fnbB* and orthopedic implant infections \[[@pone.0141436.ref032]\], though the comparator group in this prior study was *S*. *aureus* isolates that caused infections in persons without an orthopedic implant.

The PJI and PJU groups also had a similar mean fibronectin binding capacity. While the fibronectin binding assay is arguably a crude tool of measurement, it is a well-established platform and has previously detected differences in fibronectin binding capacity \[[@pone.0141436.ref015],[@pone.0141436.ref016]\]. The ability to form biofilm was also similar in the PJI and PJU groups.

Taken together, these results suggest that SNPs within *fnbA* and *fnbB* do not influence fibronectin binding, biofilm formation, or clinical outcome (PJI vs. PJU). These results stand in stark contrast to those we found in CDI as well as a recent study of *S*. *aureus* that cause infective endocarditis \[[@pone.0141436.ref033]\]. This suggests that additional factors in the environment surrounding cardiac devices, but not arthroplasties, contribute to the link between *fnbA* and *S*. *aureus* CDI.

This study has limitations. First, only *fnbA* and *fnbB* were examined. There are a variety of other MSCRAMMs beyond the scope of this study that would be of interest to sequence, such as sialoprotein-binding protein (*bbp*), clumping factor A (*clfA)*, clumping factor B (*clfB)*, collagen binding adhesion (*cna)*, or elastin-binding protein (*ebpS*). Moreover, the biological characteristic of redundancy is well known in *S*. *aureus*, making more than one mechanism possible. Second, none of the isolates lacked *fnbA*, making it impossible to assess the comparative importance of *fnbA* presence in the pathogenesis of *S*. *aureus* arthroplasty infection. Third, the growth media conditions in the assays (biofilm-forming capacity, fibronectin-binding capacity, quantitative PCR, Western ligand binding assay) differed slightly, which complicates direct comparison of assay results.

However, we conclude that genetic variation in *fnbA* and *fnbB* is not uniformly linked to the pathogenesis of foreign device infections. Instead, there appears to be a link between the physiological environment of the indwelling device, such as location, presence of a fibrin sheath, or device material, and the initiation of *S*. *aureus* prosthesis infection. Future studies are being performed to unravel this significant complication of medical progress.

Supporting Information {#sec026}
======================

###### Scatter plot of fibronectin binding capacity versus biofilm formation.

Fibronectin binding capacity was normalized to that of control strain *S*. *aureus* 8325--4, and biofilm formation was normalized to that of *S*. *aureus* UAMS-1.

(TIF)

###### 

Click here for additional data file.
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